Monami M, et al. - Using available data from randomized trials, researchers sought to establish the durability of the efficacy of sodium glucose co-transport-2 (SGLT-2) inhibitors on glycaemic control and body mass index. It was observed that HbA1c reduction at 12, 24, 52 and 104 weeks was 0.63% (0.57; 0.68, 0.63% (0.57; 0.70), 0.66% (0.57; 0.74) and 0.60% (0.40; 0.81), respectively. A good persistence of efficacy, at least up to 2 years was illustrated by SGLT-2 inhibitors. It displayed a minor yet significant superiority over dipeptidyl-peptidase-4 inhibitors (DPP-4i). The inference drawn was that sulfonylureas were more effective in the very short term but less effective in the longer term.